Emergent BioSolutions

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.6K

Market Cap: -

Website

Introduction: Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Clinical Trials

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Bacillus Anthracis (Anthrax) Infection

Interventions: Biological: AV7909 Formulation 3
Biological: AV7909 Formulation 2
Drug: Control
Biological: BioThrax
Biological: AV7909 Formulation 1
Biological: AV7909 Formulation 4

First Posted Date: 2010-12-21

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 105

Registration Number: NCT01263691

Locations: 🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Phase 1

Completed

Conditions: Anthrax

Interventions: Drug: AVP-21D9
Drug: Placebo

First Posted Date: 2010-09-16

Last Posted Date: 2024-03-15

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 50

Registration Number: NCT01202695

Locations: 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Phase 3

Completed

Conditions: Smallpox Vaccine Adverse Reaction

Interventions: Biological: ACAM2000

First Posted Date: 2010-07-08

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 25

Registration Number: NCT01158157

Locations: 🇺🇸
Cangene Plasma Resources, Mid-Florida, Altamonte Springs, Florida, United States

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Phase 1

Completed

Conditions: Bird Flu
Influenza

Interventions: Other: Placebo
Biological: Ad4-H5-Vtn
Biological: Sanofi Pasteur Influenza Virus Vaccine, H5N1

First Posted Date: 2009-11-03

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 166

Registration Number: NCT01006798

Locations: 🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸
Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 1 locations

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Completed

Conditions: Smallpox

First Posted Date: 2009-06-26

Last Posted Date: 2024-04-04

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 14108

Registration Number: NCT00928577

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Completed

Conditions: Smallpox

Interventions: Biological: ACAM2000® smallpox vaccine

First Posted Date: 2009-06-25

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 897227

Registration Number: NCT00927719

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

Phase 2

Terminated

Conditions: T-cell Lymphoma

Interventions: Biological: CHOP + CD4
Drug: CHOP

First Posted Date: 2009-05-06

Last Posted Date: 2024-04-09

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 5

Registration Number: NCT00893516

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: T Cell Lymphoma

Interventions: Biological: HuMax-CD4

First Posted Date: 2009-04-08

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 21

Registration Number: NCT00877656

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Phase 1

Completed

Conditions: Anthrax

Interventions: Biological: AIGIV 14.0 mg/kg
Biological: Gamunex 90 mg/kg
Biological: Gamunex 180 mg/kg
Biological: Gamunex 360 mg/kg
Biological: AIGIV 3.5 mg/kg
Biological: AIGIV 7.0 mg/kg

First Posted Date: 2009-02-18

Last Posted Date: 2024-03-18

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 129

Registration Number: NCT00845650

Locations: 🇺🇸
SNBL Clinical Pharmacology Center Inc., Baltimore, Maryland, United States

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Phase 2

Completed

Conditions: Typhoid

Interventions: Biological: Dose of 5.0 x 10^9 CFU (Cohort 1)
Biological: Dose of of 1.7 x 10^10 CFU (Cohort 4)
Biological: Dose of 7.5 x 10^9 CFU (Cohort 2)
Biological: Dose of 1.1 x 10^10 CFU (Cohort 3)
Other: Placebo (Cohorts 1-4 pooled)

First Posted Date: 2008-05-16

Last Posted Date: 2024-04-09

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 187

Registration Number: NCT00679172

Locations: 🇺🇸
John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸
Unit of Infectious Diseases, University of Vermont College of Medicine, Burlington, Vermont, United States
🇺🇸
Miami Research Associates, South Miami, Florida, United States

Home Terms & Conditions Privacy Policy